Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory Study
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China